Storm Therapeutics received a $56 million Series C from investors including M Ventures, Pfizer Ventures and Taiho Ventures.
05 April 2026
05 April 2026
Total investments received (USD): 86M
Round value (USD): 56M
Company: Storm Therapeutics
Industry: BiotechHealth services
Related deals
Immutrin in a £65M series A led by Frazier Life Sciences, joined by SR One, Qiming Venture Partners, Cambridge Enterprise Ventures and F-Prime
Investments
07 March 2026
R1 Therapeutics secured a $77.5 million Series A led by Abingworth, F-Prime Capital and DaVita Venture Group.
Investments
01 March 2026
Tenpoint Therapeutics raises $85M series B with Janus Henderson Investors, Hillhouse Investment, EQT and British Business Bank
Investments
30 January 2026
Bit.bio raised $50m in Series C funding round led by M&G Investments.
Investments
29 December 2025
Belgium
Austria
Denmark
Estonia
Finland
Iceland
Latvia
Lithuania
Norway
Ireland
Italy
Portugal
Spain